SI9300421A - Hepatitis a virus vaccine - Google Patents

Hepatitis a virus vaccine Download PDF

Info

Publication number
SI9300421A
SI9300421A SI9300421A SI9300421A SI9300421A SI 9300421 A SI9300421 A SI 9300421A SI 9300421 A SI9300421 A SI 9300421A SI 9300421 A SI9300421 A SI 9300421A SI 9300421 A SI9300421 A SI 9300421A
Authority
SI
Slovenia
Prior art keywords
hepatitis
hav
virus
protein
cell
Prior art date
Application number
SI9300421A
Other languages
English (en)
Slovenian (sl)
Inventor
Robert A Aboud
John G Aunins
Barry C Buckland
Peter A Dephillips
Anna J Hagen
John P Hennessey
Beth Junker
John A Lewis
Oliver Cynthia Newell
Charles J Orella
Robert D Sitrin
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of SI9300421A publication Critical patent/SI9300421A/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32451—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SI9300421A 1992-08-07 1993-08-06 Hepatitis a virus vaccine SI9300421A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92687392A 1992-08-07 1992-08-07
CN93117633A CN1099798A (zh) 1992-08-07 1993-08-06 甲型肝炎病毒疫苗

Publications (1)

Publication Number Publication Date
SI9300421A true SI9300421A (en) 1994-06-30

Family

ID=36869970

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9300421A SI9300421A (en) 1992-08-07 1993-08-06 Hepatitis a virus vaccine

Country Status (16)

Country Link
EP (1) EP0583142A2 (sk)
JP (1) JPH0748277A (sk)
CN (1) CN1099798A (sk)
AU (1) AU4450093A (sk)
CA (1) CA2103515A1 (sk)
CZ (1) CZ34795A3 (sk)
DZ (1) DZ1706A1 (sk)
FI (1) FI950567A (sk)
HU (1) HUT70982A (sk)
MX (1) MX9304803A (sk)
NO (1) NO950483L (sk)
PL (1) PL307402A1 (sk)
SI (1) SI9300421A (sk)
SK (1) SK18495A3 (sk)
WO (1) WO1994003589A2 (sk)
ZA (1) ZA935723B (sk)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0533492A3 (en) * 1991-09-18 1994-08-10 Amgen Inc A hepatitis b vaccine formulation incorporating a bile acid salt
HRP950097A2 (en) * 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
ATE371372T1 (de) * 1997-10-09 2007-09-15 Wellstat Biologics Corp Behandlung von neoplasmen mit interferon- empfindlichen, klonalen viren
AU4246900A (en) 1999-04-15 2000-11-02 Pro-Virus, Inc. Treatment of neoplasms with viruses
KR100421386B1 (ko) * 2001-09-22 2004-03-09 엘지전자 주식회사 초고속용 유도 전동기의 회전자
US6825027B2 (en) 2001-12-10 2004-11-30 Baxter Healthcare S.A. Method of production of purified hepatitis a virus particles and vaccine preparation
DE60327069D1 (de) 2002-04-30 2009-05-20 Oncolytics Biotech Inc Verbesserte reinigungsmethode für viren
GB0304799D0 (en) * 2003-03-03 2003-04-09 Glaxosmithkline Biolog Sa Novel method
WO2005070454A2 (en) * 2004-01-27 2005-08-04 Bharat Biotech International Limited A novel process of hepatitis a vaccine preparation
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
CN101816786B (zh) * 2010-04-30 2012-09-05 长春生物制品研究所有限责任公司 一种甲型肝炎灭活疫苗及其制备方法
CN102058882B (zh) * 2010-12-28 2012-12-26 深圳康泰生物制品股份有限公司 一种制备甲型肝炎灭活疫苗的方法
CN103013933B (zh) * 2012-12-14 2014-10-22 北京民海生物科技有限公司 人二倍体狂犬病疫苗病毒液的灭活方法
PL3121268T3 (pl) * 2015-07-23 2019-06-28 Grifols, S.A. Sposoby oczyszczania wirusa wytworzonego in vitro i badania klirensu wirusa
EP3695849A1 (en) * 2019-02-13 2020-08-19 Mediagnost Gesellschaft für Forschung und Herstellung von Diagnostika GmbH Method for extracting hepatitis a virus (hav) antigen from cell culture
CN112202628B (zh) * 2020-09-08 2022-09-02 杭州涂鸦信息技术有限公司 一种WiFi模块串口协议自动化测试系统及方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296204A (en) * 1978-01-25 1981-10-20 Merck & Co., Inc. Use of motionless mixer as cell culture propagator
US4164566A (en) 1978-08-17 1979-08-14 Merck & Co., Inc. Hepatitis a virus cell culture in vitro
US5021348A (en) 1979-09-04 1991-06-04 Merck & Co., Inc. Attenuated hepatitis A virus
US4415670A (en) 1980-07-07 1983-11-15 Merck & Co., Inc. Motionless mixer as cell culture propagator
US4301249A (en) * 1980-07-23 1981-11-17 Merck & Co., Inc. High titer production of hepatitis A virus
NZ225583A (en) 1987-08-06 1991-07-26 Merck & Co Inc Process for purifying hepatitis a virions (hav)
JPH0751513B2 (ja) * 1988-04-28 1995-06-05 国立予防衛生研究所長 Ａ型肝炎ワクチン
CA2047041A1 (en) * 1990-07-18 1992-01-19 John A. Lewis Process for purification of hepatitis-a virus capsids

Also Published As

Publication number Publication date
CZ34795A3 (en) 1996-03-13
HUT70982A (en) 1995-11-28
NO950483L (no) 1995-04-07
MX9304803A (es) 1994-05-31
WO1994003589A3 (en) 1994-03-31
CN1099798A (zh) 1995-03-08
CA2103515A1 (en) 1994-02-11
PL307402A1 (en) 1995-05-15
EP0583142A2 (en) 1994-02-16
NO950483D0 (no) 1995-02-09
FI950567A (fi) 1995-04-05
ZA935723B (en) 1995-03-22
FI950567A0 (fi) 1995-02-09
AU4450093A (en) 1994-02-10
JPH0748277A (ja) 1995-02-21
DZ1706A1 (fr) 2002-02-17
SK18495A3 (en) 1995-11-08
HU9500417D0 (en) 1995-04-28
WO1994003589A2 (en) 1994-02-17
EP0583142A3 (sk) 1994-04-13

Similar Documents

Publication Publication Date Title
SI9300421A (en) Hepatitis a virus vaccine
FI117513B (fi) Menetelmä PRRS-viruksen viljelemiseksi ja sen käyttö rokotteissa
Purdy et al. Preliminary evidence that a trpE‐HEV fusion protein protects cynomolgus macaques against challenge with wild‐type hepatitis E virus (HEV)
JP5264843B2 (ja) 細胞培養におけるインフルエンザウイルスの複製の方法、および本方法によって入手可能なインフルエンザウイルス
CA2197683C (en) Method for preparing an influenza virus, antigens obtained and applications thereof
CN114107221A (zh) 用于产生制备疫苗的病毒的方法
Hardy et al. Egg fluids and cells of the chorioallantoic membrane of embryonated chicken eggs can select different variants of influenza A (H3N2) viruses
PT1427817E (pt) Multiplicação de vírus numa cultura celular
US4525349A (en) Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine
Butel Studies with human papilloma virus modeled after known papovavirus systems
Mayor et al. Immunofluorescent, cytochemical, and microcytological studies on the growth of the simian vacuolating virus (SV-40) in tissue culture
Matumoto Multiplication of measles virus in cell cultures
EP2075005B1 (en) Ipv-dpt vaccine
TWI227274B (en) Enhanced immunogen for inactivated vaccine for infection with Japanese encephalitis viruses and process for producing the same
US6855535B2 (en) Method of large scale production of Hepatitis A virus
Duchene et al. Production of poliovirus vaccines: past, present, and future
CN100467062C (zh) 制备纯化的甲型肝炎病毒体和疫苗制剂的方法
Minor et al. Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains
Hamidi et al. Innovative IPV from attenuated Sabin poliovirus or newly designed alternative seed strains
HRP931103A2 (hr) Cjepivo za virus hepatitisa a
Borges et al. Biological characterization of clones derived from the Edmonston strain of measles virus in comparison with Schwarz and CAM-70 vaccine strains
Kodama et al. Studies on L cells persistently infected with polyoma virus: relationship between D particle and other virus-like particles
CN115516099A (zh) 甲型肝炎病毒制备方法和根据该方法制备的甲型肝炎病毒
Gannicliffe et al. Human papovaviruses
Epstein Vaccination against Epstein-Barr virus